See more : Sanaby Health Acquisition Corp. I (SANB) Income Statement Analysis – Financial Results
Complete financial analysis of Integra LifeSciences Holdings Corporation (IART) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integra LifeSciences Holdings Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Cybozu, Inc. (4776.T) Income Statement Analysis – Financial Results
- Goodman Group (GMG.AX) Income Statement Analysis – Financial Results
- Primo Nutraceuticals Inc. (BUGVF) Income Statement Analysis – Financial Results
- Federal Home Loan Mortgage Corporation (FREGP) Income Statement Analysis – Financial Results
- Sky Industries Limited (SKYIND.BO) Income Statement Analysis – Financial Results
Integra LifeSciences Holdings Corporation (IART)
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.37B | 1.52B | 1.47B | 1.19B | 992.08M | 882.73M | 928.31M | 836.21M | 830.87M | 780.08M | 732.07M | 682.49M | 654.60M | 550.46M | 419.30M | 277.94M | 229.83M | 185.60M | 112.63M | 93.44M | 64.99M | 42.50M | 17.50M | 14.70M | 13.10M | 10.20M |
| Cost of Revenue | 653.18M | 587.36M | 597.81M | 520.83M | 564.68M | 571.50M | 435.51M | 349.09M | 326.54M | 352.80M | 334.09M | 314.43M | 299.15M | 268.19M | 244.92M | 252.83M | 214.67M | 168.31M | 105.54M | 87.30M | 70.60M | 45.77M | 36.01M | 26.82M | 21.80M | 6.10M | 5.20M | 4.70M | 3.50M |
| Gross Profit | 888.39M | 970.31M | 944.64M | 851.03M | 952.88M | 900.95M | 752.73M | 642.99M | 556.19M | 575.50M | 502.13M | 516.44M | 480.93M | 463.88M | 437.57M | 401.78M | 335.79M | 250.98M | 172.40M | 142.53M | 115.00M | 66.85M | 57.43M | 38.17M | 20.70M | 11.40M | 9.50M | 8.40M | 6.70M |
| Gross Profit Ratio | 57.63% | 62.29% | 61.24% | 62.03% | 62.79% | 61.19% | 63.35% | 64.81% | 63.01% | 62.00% | 60.05% | 62.16% | 61.65% | 63.37% | 64.11% | 61.38% | 61.00% | 59.86% | 62.03% | 62.02% | 61.96% | 59.36% | 61.46% | 58.74% | 48.71% | 65.14% | 64.63% | 64.12% | 65.69% |
| Research & Development | 174.59M | 101.19M | 93.05M | 77.38M | 79.57M | 78.04M | 63.46M | 58.16M | 50.90M | 51.60M | 52.09M | 51.01M | 51.45M | 48.11M | 44.28M | 60.50M | 30.66M | 25.73M | 11.96M | 14.12M | 12.81M | 8.30M | 7.99M | 7.52M | 8.70M | 8.40M | 6.40M | 6.30M | 5.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 592.64M | 616.32M | 637.45M | 594.53M | 687.60M | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 6.10M |
| Other Expenses | 69.16M | 13.88M | 16.91M | 27.76M | 27.03M | 8.29M | 1.35M | 845.00K | 4.59M | -763.00K | -1.80M | -721.00K | 16.43M | 12.02M | 14.36M | 12.88M | 12.65M | 8.80M | 6.06M | 4.27M | 3.08M | -3.55M | 2.78M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| Operating Expenses | 836.39M | 731.39M | 747.41M | 699.66M | 794.20M | 789.95M | 707.92M | 527.65M | 476.61M | 509.96M | 459.04M | 442.66M | 426.02M | 365.19M | 339.75M | 354.37M | 268.50M | 192.24M | 116.29M | 117.75M | 75.36M | 45.34M | 43.14M | 56.55M | 33.10M | 25.50M | 28.50M | 17.90M | 12.70M |
| Cost & Expenses | 1.43B | 1.32B | 1.35B | 1.22B | 1.36B | 1.36B | 1.14B | 876.74M | 803.15M | 862.76M | 793.12M | 757.09M | 725.17M | 633.37M | 584.66M | 607.19M | 483.17M | 360.55M | 221.83M | 205.05M | 145.95M | 91.11M | 79.16M | 83.37M | 54.90M | 31.60M | 33.70M | 22.60M | 16.20M |
| Interest Income | 17.20M | 11.92M | 6.74M | 9.30M | 10.78M | 2.80M | 255.00K | 24.00K | 13.00K | 168.00K | 443.00K | 1.21M | 465.00K | 225.00K | 631.00K | 2.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 51.38M | 49.59M | 50.40M | 71.58M | 53.96M | 64.68M | 35.02M | 25.80M | 23.52M | 21.97M | 19.79M | 22.24M | 27.64M | 18.36M | 23.23M | 30.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.51M | 121.12M | 123.67M | 118.99M | 114.70M | 115.70M | 88.90M | 72.67M | 9.95M | 12.40M | 47.01M | 18.54M | 16.43M | 39.17M | 39.69M | 33.15M | 27.04M | 21.48M | 13.22M | 11.59M | 9.04M | 7.16M | 6.26M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| EBITDA | 274.01M | 391.10M | 366.33M | 267.93M | 231.03M | 241.04M | 135.23M | 231.73M | 195.59M | 172.24M | 40.07M | 116.46M | 106.31M | 139.64M | 136.07M | 79.34M | 67.29M | 58.74M | 69.33M | 36.37M | 48.69M | 25.81M | 20.54M | -13.21M | -12.40M | -16.60M | -17.20M | -7.50M | -4.60M |
| EBITDA Ratio | 17.77% | 17.77% | 15.57% | 14.06% | 13.57% | 9.73% | 5.62% | 13.11% | 10.66% | 8.33% | 10.61% | 11.17% | 9.21% | 18.86% | 20.24% | 12.44% | 16.60% | 19.61% | 25.21% | 14.08% | 14.39% | 22.91% | 15.97% | -32.65% | -34.12% | -83.43% | -130.61% | -71.76% | 144.12% |
| Operating Income | 111.53M | 238.92M | 197.23M | 151.37M | 178.98M | 111.00M | 44.80M | 115.34M | 79.59M | 65.54M | -3.64M | 73.78M | 54.91M | 98.69M | 97.82M | 47.41M | 67.29M | 58.74M | 56.11M | 24.78M | 39.65M | 19.19M | 14.29M | -18.38M | -12.40M | -14.10M | -19.00M | -9.50M | -6.00M |
| Operating Income Ratio | 7.23% | 15.34% | 12.79% | 11.03% | 11.79% | 7.54% | 3.77% | 11.63% | 9.02% | 7.06% | -0.44% | 8.88% | 7.04% | 13.48% | 14.33% | 7.24% | 12.22% | 14.01% | 20.19% | 10.78% | 21.36% | 17.04% | 15.29% | -28.29% | -29.18% | -80.57% | -129.25% | -72.52% | -58.82% |
| Total Other Income/Expenses | -30.46M | -25.03M | 17.45M | -57.85M | -33.66M | -53.60M | -33.42M | -24.93M | -18.92M | -24.88M | -21.15M | -21.75M | -26.42M | -16.58M | -24.67M | -16.41M | -7.23M | -10.44M | -1.00M | 3.23M | 3.54M | 3.54M | 1.26M | 7.54M | 7.43M | 5.26M | 2.00M | 1.90M | -19.30M |
| Income Before Tax | 81.07M | 213.89M | 214.68M | 93.52M | 60.10M | 57.40M | 11.39M | 90.41M | 60.67M | 42.98M | -24.79M | 52.03M | 28.49M | 82.11M | 73.15M | 31.01M | 60.06M | 48.31M | 55.10M | 28.01M | 43.19M | 22.73M | 15.54M | -10.85M | -7.80M | -12.30M | -17.00M | -7.60M | -25.30M |
| Income Before Tax Ratio | 5.26% | 13.73% | 13.92% | 6.82% | 3.96% | 3.90% | 0.96% | 9.11% | 6.87% | 4.63% | -2.96% | 6.26% | 3.65% | 11.22% | 10.72% | 4.74% | 10.91% | 11.52% | 19.83% | 12.19% | 23.27% | 20.18% | 16.63% | -16.69% | -18.35% | -70.29% | -115.65% | -58.02% | -248.04% |
| Income Tax Expense | 13.33M | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M | -53.36M | 15.84M | 53.82M | 8.98M | -7.81M | 10.83M | 505.00K | 16.45M | 22.20M | -3.93M | 26.59M | 18.90M | 17.91M | 10.81M | 16.33M | -12.55M | -10.86M | 108.00K | -1.80M | -1.80M | -2.00M | -2.00M | 19.40M |
| Net Income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M | -3.52M | 34.00M | -16.98M | 41.20M | 27.99M | 65.67M | 50.96M | 34.93M | 33.47M | 29.41M | 37.19M | 17.20M | 26.86M | 35.28M | 26.16M | -11.43M | -6.00M | -12.30M | -17.00M | -7.50M | -25.40M |
| Net Income Ratio | 4.39% | 11.59% | 10.96% | 9.76% | 3.31% | 4.13% | 5.45% | 7.52% | -0.40% | 3.66% | -2.03% | 4.96% | 3.59% | 8.97% | 7.47% | 5.34% | 6.08% | 7.01% | 13.38% | 7.48% | 14.47% | 31.32% | 28.00% | -17.58% | -14.12% | -70.29% | -115.65% | -57.25% | -249.02% |
| EPS | 0.87 | 2.18 | 2.00 | 1.58 | 0.59 | 0.73 | 0.83 | 1.00 | -0.05 | 0.52 | -0.30 | 0.74 | 0.52 | 1.11 | 0.88 | 0.49 | 0.61 | 0.50 | 0.62 | 0.28 | 0.46 | 0.61 | 0.54 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| EPS Diluted | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | -0.05 | 0.52 | -0.29 | 0.72 | 0.48 | 1.09 | 0.87 | 0.48 | 0.56 | 0.49 | 0.57 | 0.28 | 0.43 | 0.57 | 0.47 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| Weighted Avg Shares Out | 78.17M | 83.00M | 84.70M | 84.65M | 85.64M | 82.86M | 78.39M | 74.72M | 73.88M | 65.48M | 56.83M | 55.90M | 53.66M | 59.10M | 58.08M | 55.56M | 55.42M | 58.60M | 60.39M | 60.13M | 58.14M | 58.04M | 46.71M | 35.11M | 33.60M | 32.28M | 29.57M | 28.11M | 20.99M |
| Weighted Avg Shares Out (Dil) | 80.34M | 83.52M | 85.49M | 85.23M | 86.49M | 84.45M | 79.12M | 79.19M | 73.88M | 65.92M | 57.60M | 57.03M | 58.99M | 60.30M | 58.58M | 56.76M | 59.16M | 65.49M | 69.13M | 62.20M | 66.21M | 61.79M | 55.59M | 35.11M | 34.12M | 32.28M | 29.57M | 28.11M | 20.99M |
Reasons to Retain IART Stock in Your Portfolio for Now
Integra's strong growth in the CSS business segment bolsters investors' confidence in the stock. Meanwhile, the weak liquidity position adds to the worry.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
Integra's DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of fibrin glue The health economic analysis, conducted in five...
Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure
IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.
Integra LifeSciences Holdings Corporation (IART) Q3 2024 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward - IR Stuart Essig - Executive Chairman Jan De Witte - President and CEO Lea Knight - CFO Conference...
Integra (IART) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
Integra LifeSciences (IART) Beats Q3 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago.
Integra LifeSciences Reports Third Quarter 2024 Financial Results
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024.
Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer
A proven healthcare executive with deep global expertise and a distinguished record in business strategy and execution, portfolio transformation, value-creating innovation, commercial excellence, and leadership development A proven healthcare executive with deep global expertise and a distinguished record in business...
Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024
PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release,...
Source: https://incomestatements.info
Category: Stock Reports